DK1355641T3 - Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer - Google Patents

Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer

Info

Publication number
DK1355641T3
DK1355641T3 DK02719742T DK02719742T DK1355641T3 DK 1355641 T3 DK1355641 T3 DK 1355641T3 DK 02719742 T DK02719742 T DK 02719742T DK 02719742 T DK02719742 T DK 02719742T DK 1355641 T3 DK1355641 T3 DK 1355641T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
methanesulfonamide
ibuprofen
rejection reactions
Prior art date
Application number
DK02719742T
Other languages
Danish (da)
English (en)
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Application granted granted Critical
Publication of DK1355641T3 publication Critical patent/DK1355641T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK02719742T 2001-02-02 2002-01-30 Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer DK1355641T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (1)

Publication Number Publication Date
DK1355641T3 true DK1355641T3 (da) 2005-10-17

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02719742T DK1355641T3 (da) 2001-02-02 2002-01-30 Anvendelse af (R)-ibuprofen-methansulfonamid og salte deraf ved behandling og forebyggelse af afstödningsreaktioner i transplanterede organer

Country Status (26)

Country Link
US (1) US7560487B2 (enExample)
EP (1) EP1355641B1 (enExample)
JP (1) JP2004517948A (enExample)
KR (1) KR100857898B1 (enExample)
CN (1) CN1561205A (enExample)
AT (1) ATE304846T1 (enExample)
AU (1) AU2002250869B2 (enExample)
BR (2) BRPI0206804B1 (enExample)
CA (1) CA2432432C (enExample)
CZ (1) CZ303665B6 (enExample)
DE (1) DE60206245T2 (enExample)
DK (1) DK1355641T3 (enExample)
EE (1) EE05233B1 (enExample)
ES (1) ES2248541T3 (enExample)
HU (1) HU229070B1 (enExample)
IL (1) IL157180A (enExample)
IT (1) ITMI20010206A1 (enExample)
MX (1) MXPA03006686A (enExample)
NO (1) NO334285B1 (enExample)
NZ (1) NZ526655A (enExample)
PL (1) PL215109B1 (enExample)
PT (1) PT1355641E (enExample)
RU (1) RU2257895C2 (enExample)
SK (1) SK287632B6 (enExample)
WO (1) WO2002062330A2 (enExample)
ZA (1) ZA200304861B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (de) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
HUE065802T2 (hu) * 2017-03-15 2024-06-28 Numares Ag Marker-készlet alkalmazása vesekilökõdés kockázatának meghatározására

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
PL363576A1 (en) 2004-11-29
EE05233B1 (et) 2009-12-15
ZA200304861B (en) 2004-06-30
IL157180A (en) 2009-06-15
RU2003126600A (ru) 2005-02-27
MXPA03006686A (es) 2004-05-31
NO20033273D0 (no) 2003-07-18
ES2248541T3 (es) 2006-03-16
PT1355641E (pt) 2005-11-30
HU229070B1 (hu) 2013-07-29
SK9732003A3 (en) 2003-11-04
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
CA2432432A1 (en) 2002-08-15
HUP0303024A2 (hu) 2003-12-29
DE60206245T2 (de) 2006-06-14
NO20033273L (no) 2003-07-18
SK287632B6 (sk) 2011-04-05
NO334285B1 (no) 2014-01-27
WO2002062330A2 (en) 2002-08-15
EP1355641B1 (en) 2005-09-21
NZ526655A (en) 2005-02-25
RU2257895C2 (ru) 2005-08-10
EE200300340A (et) 2003-10-15
EP1355641A2 (en) 2003-10-29
WO2002062330A3 (en) 2003-04-03
CZ303665B6 (cs) 2013-02-20
AU2002250869B2 (en) 2006-10-19
CN1561205A (zh) 2005-01-05
PL215109B1 (pl) 2013-10-31
CA2432432C (en) 2008-03-25
CZ20032095A3 (en) 2004-05-12
JP2004517948A (ja) 2004-06-17
KR100857898B1 (ko) 2008-09-10
BR0206804A (pt) 2004-02-03
ATE304846T1 (de) 2005-10-15
KR20030074725A (ko) 2003-09-19
US20040102520A1 (en) 2004-05-27
ITMI20010206A1 (it) 2002-08-02
HUP0303024A3 (en) 2005-07-28
DE60206245D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
DK1782825T3 (da) Behandling af glycogenlagringssygdom type II
SE9904176D0 (sv) New use
CY1116107T1 (el) Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων
EA200400432A1 (ru) Производные мочевины
DK1336605T3 (da) Substituerede phenolderivater eller salte deraf som inhibitorer af koagulationsfaktor X
BR9909668A (pt) Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
BR0212924A (pt) Inibidores de glicogênio sintase quinase-3 (gsk-3) para o tratamento de glaucoma
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
DE50310516D1 (de) Fredericamycin-derivate
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
EP1350511A4 (en) MEDICAL COMPOSITIONS CONTAINING ASPIRIN
TR200003200T2 (tr) Faktör XA'yı önleyen heterosiklik türevler.
MXPA03006686A (es) Uso de metanosulfonamida de ( r ) ibuprofen y sales de la misma en el tratamiento y prevencion de las reacciones de rechazo de organos transplantados.
TW200508218A (en) Inhibitors of papilloma virus
DK1001792T3 (da) Anvendelse af fysiologisk acceptable vanadiumforbindelser, -salte og -komplekser
BR9608506A (pt) "2-Amino-benzoxazinonas para o tratamento de infeccões viróticas
EA199700106A1 (ru) Замещенные 2-фенилпиридины в качестве гербицидов
FR2849598B1 (fr) Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
BR0207434A (pt) Uso de agentes de domiciliação acelerada de linfócitos para a fabricação de um medicamento para o tratamento de função retardada de enxertos
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
JP2004517948A5 (enExample)
DE60039782D1 (de) Amidinophenylbrenztraubensäure-derivat
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie